PLYMOUTH MEETING, Pa.,
March 25, 2019 /PRNewswire/ -- Inovio
Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment
of Dr. Ann C. Miller to its Board of
Directors. Dr. Miller had an outstanding marketing career launching
and building blockbuster products for Merck, Amgen, Eisai and
Sanofi. While at Sanofi, she led the Sanofi Oncology Global
Marketing function including its pipeline, launch, and life cycle
management activities. Prior to Sanofi, Dr. Miller served as Senior
Vice President at Eisai, including leading the Primary Care and
Specialty Business unit with the blockbusters Aricept®
and Aciphex® and the enterprise-wide service platform
for the Oncology and Primary Care businesses. At Amgen, Dr. Miller
contributed to building the Global Marketing function; as Executive
Director, Global Marketing, Oncology Therapeutic Area she provided
commercialization and life cycle management oversight for key
products including Neulasta® and Vectibix®.
During her 16-year career at Merck & Co. she held numerous
positions of increasing responsibility including brand lead for
such billion-dollar products as Fosamax®,
Mevacor®, and Zocor®. Dr. Miller holds MD and
BA degrees with honors from Duke
University.
![Inovio Pharmaceuticals. (PRNewsFoto/Inovio Pharmaceuticals, Inc.) Inovio Pharmaceuticals. (PRNewsFoto/Inovio Pharmaceuticals, Inc.)](https://mma.prnewswire.com/media/13217/inovio_pharmaceuticals_inc_logo4109_21100jpg.jpg)
Dr. J. Joseph Kim, President and
CEO, said, "Dr. Miller's expertise will help guide us as we
transition to a commercial organization. We will benefit from her
clinical training and extensive experience developing and executing
launch and growth strategies across a wide range of oncology,
specialty and primary care portfolios and
products."
Inovio is in late-stage development for several of its product
candidates. Inovio's lead product, VGX-3100, for HPV-caused
cervical dysplasia, is advancing in global Phase 3 trials. Inovio
is developing its HPV program in Phase 2 trials treating HPV-caused
vulvar and anal dysplasia. Inovio's technology platform is
demonstrating its versatility in two Phase 2 oncology combination
trials integrating Inovio's INO-5401 therapy with several
checkpoint inhibitors from Genentech/Roche (for bladder cancer,)
and Regeneron (for brain cancer (GBM)). MEDI0457 (VGX-3100 +
pIL-12, which Inovio licensed to AstraZeneca) is in Phase 2
combination trials with durvalumab targeting head & neck cancer
and cervical cancer in addition to a broad array of other cancers
associated with the human papilloma virus. Inovio's infectious
disease pipeline is also moving vaccines into late-stage trials for
Lassa fever, Ebola, MERS and HIV.
About Inovio Pharmaceuticals, Inc.
Inovio is a late-stage biotechnology company focused on the
discovery, development, and commercialization of DNA-based
immunotherapies and vaccines that transform the treatment and
prevention of cancer and infectious disease. Inovio's
proprietary technology platform applies antigen sequencing and DNA
delivery to activate potent immune responses to targeted
diseases. The technology functions exclusively in vivo,
and has been demonstrated to consistently activate robust and fully
functional T cell and antibody responses against targeted cancers
and pathogens. Inovio's most advanced clinical program, VGX-3100,
is in Phase 3 for the treatment of HPV-related cervical
pre-cancer. Also in development are Phase 2 immuno-oncology
programs targeting HPV-related cancers, bladder cancer, and
glioblastoma, as well as platform development programs in hepatitis
B, Zika, Ebola, MERS, and HIV. Partners and collaborators
include AstraZeneca, Regeneron, Roche/Genentech, ApolloBio
Corporation, The Wistar Institute, The Bill & Melinda Gates
Foundation, the University of
Pennsylvania, Parker Institute for Cancer Immunotherapy,
CEPI, DARPA, GeneOne Life Science, Plumbline Life Sciences, NIH,
HIV Vaccines Trial Network, National Cancer Institute, Walter Reed
Army Institute of Research, Drexel
University, and Laval University. For more information,
visit www.inovio.com.
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines, our expectations regarding our research and development
programs, including the planned initiation and conduct of clinical
trials and the availability and timing of data from those trials.
Actual events or results may differ from the expectations set forth
herein as a result of a number of factors, including uncertainties
inherent in pre-clinical studies, clinical trials and product
development programs, the availability of funding to support
continuing research and studies in an effort to prove safety and
efficacy of electroporation technology as a delivery mechanism or
develop viable DNA vaccines, our ability to support our pipeline of
SynCon® active immunotherapy and vaccine products, the ability of
our collaborators to attain development and commercial milestones
for products we license and product sales that will enable us to
receive future payments and royalties, the adequacy of our capital
resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by
us or our collaborators, including alternatives that may be more
efficacious or cost effective than any therapy or treatment that we
and our collaborators hope to develop, issues involving product
liability, issues involving patents and whether they or licenses to
them will provide us with meaningful protection from others using
the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
we can finance or devote other significant resources that may be
necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of our technology by potential
corporate or other partners or collaborators, capital market
conditions, the impact of government healthcare proposals and other
factors set forth in our Annual Report on Form 10-K for the year
ended December 31, 2018 and other
regulatory filings we make from time to time. There can be no
assurance that any product candidate in our pipeline will be
successfully developed, manufactured or commercialized, that final
results of clinical trials will be supportive of regulatory
approvals required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate. Forward-looking statements speak only as of the date of
this release, and we undertake no obligation to update or revise
these statements, except as may be required by law.
CONTACTS:
|
|
Investors:
|
Ben Matone, Inovio,
484-362-0076, ben.matone@inovio.com
|
Media:
|
Jeff Richardson,
Inovio, 267-440-4211, jrichardson@inovio.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/inovio-appoints-global-commercial-leader-to-its-board-of-directors-300816582.html
SOURCE Inovio Pharmaceuticals, Inc.